中华皮肤科杂志 ›› 2009, Vol. 42 ›› Issue (3): 193-196.

• 论著 • 上一篇    下一篇

阿维A对鼠B16黑素瘤的增殖抑制及诱导分化作用

丁政云 杨阳   

  1. 河北医科大学第四医院皮肤科 河北医科大学第四医院皮肤科
  • 收稿日期:2008-04-07 修回日期:2008-07-24 出版日期:2009-03-15 发布日期:2009-03-15
  • 通讯作者: 丁政云 E-mail:graceyy-80cn@163.com

Acitretin inhibits the growth and induces the differentiation of mouse B16 melanoma

  • Received:2008-04-07 Revised:2008-07-24 Online:2009-03-15 Published:2009-03-15

摘要:

目的 探讨阿维A对鼠B16黑素瘤移植瘤的增殖抑制及诱导分化可能的作用机制。方法 小鼠黑素瘤B16细胞接种C57BL/6J小鼠,观察阿维A及其联合顺铂对移植瘤生长状态的影响。应用HE染色观察移植瘤形态学改变;免疫组化法检测肿瘤组织中生存素、促细胞凋亡蛋白Fas及血管内皮生长因子(VEGF)的表达。结果 阿维A能显著抑制鼠B16黑素瘤的生长,各治疗组瘤重及瘤体积均低于阴性对照组(P < 0.05)。HE染色观察瘤组织:对照组瘤组织边界不清,细胞密集排列,异形性明显,治疗组瘤组织中心及边缘可见不同程度的大片状或灶性坏死。免疫组化结果显示:生存素和VEGF蛋白的表达在阿维A高剂量组及联合用药组的免疫组化评分分别为3.600 ± 0.966,2.100 ± 0.568和4.600 ± 0.966,2.400 ± 0.516,均低于对照组5.900 ± 1.370,6.100 ± 1.197(P < 0.01,P < 0.01),Fas蛋白的表达均高于对照组(P < 0.01),且各治疗组生存素的表达与Fas的表达呈负相关(rs = -0.77,P < 0.01),与VEGF的表达成正相关(rs = 0.72,P < 0.01)。结论 阿维A能抑制鼠B16黑素瘤增殖,诱导其分化,作用机制可能与下调抑凋亡基因生存素、上调促凋亡基因Fas的表达及抑制VEGF的表达有关。

关键词: 阿维A酸;恶性黑色素瘤;顺铂;Survivin;Fas;VEGF

Abstract:

Objective To study the inhibition of growth and induction of differentiation of mouse B16 melanoma by acitretin and their mechanism. Methods Animal models of B16 melanoma were established by subcutaneously inoculation of cultured B16 cells into the right axilla of mice. All mice were divided into 5 groups, negative control group treated with peanut oil, low-dose acitretin group treated with acitretin 10 mg per kilogram of body weight per day, high-dose acitretin group treated with 20 mg per kilogram body weight per day, cisplatin group treated with cisplatin 10 mg per kilogram body weight, combination group treated with acitretin 20 mg per kilogram body weight per day plus cisplatin 10 mg per kilogram body weight. Acitretin was given daily via intragastric administration, and cisplatin was given with an interval of 7 days, from day 2 till day 22 after the inoculation. The growth of transplanted tumor was measured with an interval of 3 days. After drug withdrawal, mice were killed, transplanted tumors were obtained for the measurement of tumor weight, pathological examination and immunohistochemical staining for survivin, Fas and vascular endothelial growth factor (VEGF). Results Acitretin could significantly inhibit the growth of B16 melanoma, the average weight and volume of transplanted tumor in the treated groups were significantly lower than those in the negative control group (all P < 0.01). Pathological examination revealed that in the control group, tumor cells showed typical heteromorphism, and closely arranged with an obscure boundary, whereas in the treated groups, a massive or focal necrosis at different levels was observed in the center and margin of tumor tissue. The relative expression levels of suvivin, VEGF and Fas protein were 3.600 ± 0.966, 4.600 ± 0.966, 4.300 ± 0.949 respectively, in high-dose acitretin group, 2.100 ± 0.568, 2.400 ± 0.516, 5.900 ± 0.730 respectively, in combination group, 5.900 ± 1.370, 6.100 ± 1.197, 2.100 ± 0.568, respectively, in the negative control group, and a significant decrease was observed in the expression of suvivin and VEGF in the former two groups along with an increase in Fas expression compared with the negative control group (all P < 0.01). Additionally, in all the treated mice, the expression of survivin was negatively correlated to that of Fas (rs = -0.77, P < 0.01), but positively to that of VEGF (rs = 0.72, P < 0.01). Conclusions Acitretin can obviously inhibit the growth and induce the differentiation of B16 melanoma, which may be associated with its downregulation of survivin and VEGF expression as well as the upregulation of Fas expression.

Key words: Acitretin;malignant melanoma;CDDP;Survivin;Fas;VEGF